Back to search

Article

Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers

2023-09-29

Abstract excerpt

CDK4/6 inhibitors (CDK4/6i) have transformed the treatment of hormone receptor-positive (HR+), HER2-negative (HR+) breast cancers as they are effective across all clinicopathological, age, and ethnicity subgroups for metastatic HR+ breast cancer. In metastatic ER+ breast cancer, CDK4/6i lead to strong and consistent improvement in survival across different lines of therapy. To improve understanding of how metastat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
45500697-6ffb-53cf-91eb-5a9dd2cb34b7
DOI
10.1101/2023.09.27.557464
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancersDOI 10.1101/2023.09.27.557464
An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast CancerSemantic proximity
An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancerSemantic proximity
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast CancerSemantic proximity
From Static to Dynamic: Adaptive Molecular Subtyping in Treated Breast Cancers—Evidence from Single‐Center Retrospective Cohort StudySemantic proximity
Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity
Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasisSemantic proximity
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity
Dynamic Tumor Immune Microenvironment Remodeling Predicts Response of Checkpoint Inhibitor TherapySemantic proximity
The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.